Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32503
Title: Serum levels of macrophage-colony stimulating factor (M-CSF): A marker of kidney allograft rejection.
Authors: Praloran V.;Mons S.;Jose M.;Dantal J.;Lemauff B.;Aldigier J.-C.;Leroux-Robert C.;Le Meur Y.;Leprivey-Lorgeot V.
Institution: (Le Meur, Mons, Aldigier, Leroux-Robert) Service de Nephrologie, Ctr. Hospitalier Univ. Dupuytren, 2 rue Martin Luther King, F-87042 Limoges Cedex, France (Leprivey-Lorgeot) Laboratoire de Physiologie, Faculte de Medecine, Limoges, France (Jose) Renal Laboratory, Monash Medical Centre, Melbourne, Vic., Australia (Dantal, Lemauff) Serv. de Nephrol. et Immunol. Clin., Centre Hospitalier Universitaire, Nantes, France (Praloran) Lab. Universitaire d'Hematologie, Universite Victor Segalen, Bordeaux, France
Issue Date: 18-Oct-2012
Copyright year: 2004
Publisher: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom)
Place of publication: United Kingdom
Publication information: Nephrology Dialysis Transplantation. 19 (7) (pp 1862-1865), 2004. Date of Publication: June 2004.
Abstract: Background. Macrophage-colony stimulating factor (M-CSF) is the principal factor for survival of monocytes and macrophages that play an important role in allograft rejection. We studied M-CSF serum levels during successful renal transplantation and acute graft rejection. Methods. A total of 114 kidney allograft recipients were assessed for M-CSF levels by enzyme-linked immunosorbent assay (ELISA). Results. M-CSF serum levels were elevated in pretransplant haemodialysis patients (611+/-355 IU/ml vs 168+/-61 in normal controls, P<0.01). Following successful renal transplantation, M-CSF decreased in the first month, stabilizing at 257+/-222IU/ml (not significantly different from normal controls) in 52 post-transplant stable patients. There was no correlation between M-CSF level and creatinine clearance. M-CSF levels increased significantly (2-5 times) during biopsy-proven acute rejection episodes in 20 of 25 patients. All rejection episodes were successfully treated and serum M-CSF decreased rapidly to pre-rejection levels in 17/20 patients. In contrast, in five patients with cyclosporin toxicity and four patients with other causes of allograft dysfunction, M-CSF serum levels did not change. Conclusions. M-CSF serum level might be a specific marker of acute rejection. The source of increased production during rejection warrants further investigation, with infiltrating T cells and resident kidney cells being likely candidates. © ERA-EDTA 2004; all rights reserved.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/ndt/gfh257
PubMed URL: 15150350 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15150350]
ISSN: 0931-0509
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/32503
Type: Article
Appears in Collections:Articles

Show full item record

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.